Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2010122134) NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2010/122134 International Application No.: PCT/EP2010/055417
Publication Date: 28.10.2010 International Filing Date: 23.04.2010
IPC:
C07D 223/16 (2006.01) ,A61K 31/55 (2006.01) ,A61P 25/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
223
Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
14
condensed with carbocyclic rings or ring systems
16
Benzazepines; Hydrogenated benzazepines
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
Applicants:
WÜNSCH, Bernhard [DE/DE]; DE (UsOnly)
TEWES, Bastian [DE/DE]; DE (UsOnly)
SCHEPMANN, Dirk [DE/DE]; DE (UsOnly)
WESTFÄLISCHE WILHELMS UNIVERSITÄT MÜNSTER [DE/DE]; Schlossplatz 2 48149 Münster, DE (AllExceptUS)
Inventors:
WÜNSCH, Bernhard; DE
TEWES, Bastian; DE
SCHEPMANN, Dirk; DE
Agent:
ALTHAUSEN, Sonja; Michalski Hüttermann & Partner Association No. 289 Neuer Zollhof 2 40221 Düsseldorf, DE
Priority Data:
09158697.424.04.2009EP
Title (EN) NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS
(FR) ANTAGONISTES DES RÉCEPTEURS NMDA SÉLECTIFS DU SITE NR2B
Abstract:
(EN) The present invention relates to compounds according to general formula (I) and pharmaceutical compositions comprising compounds according to general formula (I).
(FR) La présente invention concerne des composés de formule développée (I) et des compositions pharmaceutiques comprenant des composés de formule développée (I).
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)